ALGS

Aligos Therapeutics (ALGS)

About Aligos Therapeutics (ALGS)

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Details

Daily high
$7.60
Daily low
$6.98
Price at open
$7.59
52 Week High
$30.00
52 Week Low
$6.76
Market cap
24.4M
Dividend yield
0.00%
Volume
75,676
Avg. volume
105,963
P/E ratio
--

Aligos Therapeutics News

Details

Daily high
$7.60
Daily low
$6.98
Price at open
$7.59
52 Week High
$30.00
52 Week Low
$6.76
Market cap
24.4M
Dividend yield
0.00%
Volume
75,676
Avg. volume
105,963
P/E ratio
--